China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its antibody drug conjugate (ADC) DXC005 in a clinical study at Beijing Cancer Hospital’s gastrointestinal oncology department. The trial marks progress in DAC Bio’s pipeline of oncology-focused ADC candidates.
Drug Profile
DXC005 combines a MUC-1 targeting antibody with a cysteine-linked tubulysin B analog (Tub201) payload. Tubulysin inhibits microtubule polymerization, arresting cell division in the G2/M phase and inducing apoptosis. The drug class is noted for bystander activity and efficacy against multidrug-resistant cancer cells, distinguishing it from other microtubule disruptors.
Company Background
Founded in 2012, DAC Biotech has over 20 ADC candidates in development, with five in clinical stages. The firm focuses on oncology and rare disease therapies, leveraging its ADC platform to deliver targeted payloads to tumor cells.-Fineline Info & Tech
